Rx Times Pharmacy Magazine

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

Rx Times — Sat, 18 Jul 2009 01:18:21 +0000

BIRMINGHAM, Ala., July 17 — BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

Rx Times — Sat, 18 Jul 2009 01:14:41 +0000

RESEARCH TRIANGLE PARK, N.C., July 17 – AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

Rx Times — Sat, 18 Jul 2009 01:08:20 +0000

SAN DIEGO, July 17 — Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3...

Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent

Rx Times — Fri, 17 Jul 2009 00:30:57 +0000

VANCOUVER, July 16 - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S....

Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System

Rx Times — Fri, 17 Jul 2009 00:28:24 +0000

SAN DIEGO, July 16 — Zogenix, Inc. (”Zogenix”), a privately held pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration...

Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)

Rx Times — Fri, 17 Jul 2009 00:25:33 +0000

PITTSBURGH, July 16 — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

Rx Times — Wed, 15 Jul 2009 23:07:11 +0000

HORSHAM, Pa., July 15 – Based on the data presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of DOXIL(R)...

Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)

Rx Times — Wed, 15 Jul 2009 23:04:42 +0000

MORRISTOWN, N.J., July 15 — Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

Rx Times — Wed, 15 Jul 2009 23:02:22 +0000

KENILWORTH, N.J., July 15 — Schering-Plough Corporation (NYSE: SGP) today announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

Rx Times — Wed, 15 Jul 2009 22:59:51 +0000

BOSTON and EDISON, N.J., July 15 – A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with...